Analysts Expect CytomX Therapeutics, Inc. (NASDAQ:CTMX) Will Post Earnings of -$0.35 Per Share

Wall Street analysts expect CytomX Therapeutics, Inc. (NASDAQ:CTMXGet Rating) to announce ($0.35) earnings per share for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for CytomX Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.26) and the lowest estimate coming in at ($0.42). CytomX Therapeutics reported earnings per share of ($0.26) during the same quarter last year, which would indicate a negative year over year growth rate of 34.6%. The company is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that CytomX Therapeutics will report full year earnings of ($1.60) per share for the current fiscal year, with EPS estimates ranging from ($1.88) to ($1.17). For the next financial year, analysts expect that the company will post earnings of ($1.70) per share, with EPS estimates ranging from ($2.34) to ($1.23). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover CytomX Therapeutics.

CytomX Therapeutics (NASDAQ:CTMXGet Rating) last announced its earnings results on Tuesday, March 1st. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.18). CytomX Therapeutics had a negative net margin of 120.18% and a negative return on equity of 69.96%. During the same quarter last year, the company earned ($0.31) earnings per share.

Several analysts recently issued reports on CTMX shares. Barclays raised shares of CytomX Therapeutics from an “underweight” rating to an “overweight” rating and set a $7.00 price objective for the company in a research note on Tuesday, January 18th. Zacks Investment Research lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, February 2nd. StockNews.com initiated coverage on shares of CytomX Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of CytomX Therapeutics in a research report on Friday, March 4th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of CytomX Therapeutics from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 2nd. Two equities research analysts have rated the stock with a sell rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.83.

NASDAQ CTMX traded down $0.12 on Wednesday, reaching $2.55. 32,960 shares of the company’s stock traded hands, compared to its average volume of 878,654. CytomX Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $10.05. The business has a 50 day moving average of $3.59.

Several hedge funds have recently made changes to their positions in CTMX. Los Angeles Capital Management LLC boosted its stake in CytomX Therapeutics by 22.3% during the 3rd quarter. Los Angeles Capital Management LLC now owns 87,723 shares of the biotechnology company’s stock valued at $447,000 after acquiring an additional 16,000 shares during the last quarter. GSA Capital Partners LLP bought a new position in CytomX Therapeutics during the 3rd quarter valued at $1,268,000. Panagora Asset Management Inc. boosted its stake in CytomX Therapeutics by 20.4% during the 3rd quarter. Panagora Asset Management Inc. now owns 112,816 shares of the biotechnology company’s stock valued at $574,000 after acquiring an additional 19,123 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of CytomX Therapeutics by 16.5% during the third quarter. Goldman Sachs Group Inc. now owns 1,109,065 shares of the biotechnology company’s stock worth $5,645,000 after purchasing an additional 157,048 shares during the period. Finally, Affinity Asset Advisors LLC raised its holdings in shares of CytomX Therapeutics by 66.7% during the third quarter. Affinity Asset Advisors LLC now owns 125,000 shares of the biotechnology company’s stock worth $636,000 after purchasing an additional 50,000 shares during the period. Institutional investors and hedge funds own 92.79% of the company’s stock.

CytomX Therapeutics Company Profile (Get Rating)

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.

Further Reading

Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.